| 1 | Oral frailty and neurodegeneration in Alzheimer’s disease显示文摘Frailty is a critical intermediate status of the aging process with a multidimensional and multisystem nature and at higher risk for adverse health-related outcomes,including falls,disability,hospitalizations,institutionalization,mortality,dementia,and Alzheimer’s disease.Among different frailty phenotypes,oral frailty has been recently suggested as a novel construct defined as a decrease in oral function with a coexisting decline in cognitive and physical functions.We briefly reviewed existing evidence on operational definitions of oral frailty,assessment and screening tools,and possible relationships among oral frailty,oral microbiota,and Alzheimer’s disease neurodegeneration.Several underlying mechanism may explain the oral health-frailty links including undernutrition,sarcopenia linked to both poor nutrition and frailty,psychosocial factors,and the chronic inflammation typical of oral disease.Oral microbiota may influence Alzheimer’s disease risk through circulatory or neural access to the brain and the interplay with periodontal disease,often causing tooth loss also linked to an increased Alzheimer’s disease risk.On this bases,COR388,a bacterial protease inhibitor targeting Porphyromonas gingivalis implicated in periodontal disease,is now being tested in a double-blind,placebocontrolled Phase II/III study in mild-to-moderate Alzheimer’s disease.Therefore,oral status may be an important contributor to general health,including Alzheimer’s disease and latelife cognitive disorders,suggesting the central role of preventive strategies targeting the novel oral frailty phenotype and including maintenance and improvement of oral function and nutritional status to reduce the burden of both oral dysfunction and frailty. | Vittorio Dibello Madia Lozupone Daniele Manfredini Antonio Dibello Roberta Zupo Rodolfo Sardone Antonio Daniele Frank Lobbezoo Francesco Panza | 2021 | Neural Regeneration Research2021，16，11： | 10 |
| 7 | 甲状腺不确定结节的回顾性细胞学评估研究(英文)显示文摘目的:回顾性分析了130例甲状腺不确定结节的临床评估和预后,以及组织细胞学检测结果,为甲状腺结节的治疗提供合理的治疗方法。方法:根据英国甲状腺协会2014年分类,回顾性分析了2011年1月至2014年12月130例甲状腺不确定结节(Thy 3)的细胞学检查。将结节分为Thy 3a(非典型特征)和Thy 3f(滤泡病变)两类。比较评估术前生物化学检查、彩色多普勒超声检查(US)、半定量弹性超声成像(USE)、超声造影(CEUS)、细胞学、组织学以及分子生物学突变分析等结果。结论:Thy 3结节的恶性肿瘤发生率较低,且在Thy 3a和Thy 3f之间没有显著差异。使用基于组织学的截取值作为参考可以降低采用手术的治疗方案。在阴性突变的Thy 3a和Thy 3f结节中,当不是所有的仪器检测结果都疑是阳性时,组织学观察应该作为首选。 | Massimo GIUSTI Barbara MASSA Margherita BALESTRA Paola CALAMARO Stefano GAY Simone SCHIAFFINO Giovanni TURTULICI Simonetta ZUPO Eleonora MONTI Gianluca ANSALDO | 2017 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2017，18，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员